Benzyl isothiocyanate (BITC) is a naturally occurring compound found in cruciferous vegetables such as broccoli, watercress, and mustard. Recent preclinical studies have indicated that BITC may possess chemopreventive and chemoprotective properties, particularly in the context of cancer chemotherapy. Scientific interest has focused on BITC’s ability to modulate detoxification enzymes, induce apoptosis in cancer cells, and exert antioxidant effects, which could theoretically reduce the side effects of chemotherapy by protecting normal cells from oxidative damage and enhancing the body’s detoxification pathways.

In animal models and in vitro studies, BITC has demonstrated cytoprotective effects against certain chemotherapeutic agents, such as doxorubicin, by reducing oxidative stress and inflammation. Some research also suggests BITC may sensitize cancer cells to chemotherapy while sparing normal cells, thus potentially reducing required dosages and associated toxicities. However, there is a lack of large-scale clinical trials in humans specifically examining BITC as an adjunct to chemotherapy for reducing side effects.

While the mechanistic and preclinical data are promising, human evidence remains limited. As such, the current support for BITC’s use to reduce the side effects of chemotherapy is based on early scientific findings, not clinical consensus or widespread clinical use.